

## 大肠癌相关蛋白抗体

产品货号： mlR17656

英文名称： SPG11

中文名称： 大肠癌相关蛋白抗体

别名： Colorectal carcinoma associated protein; Colorectal carcinoma-associated protein; DKFZp762B1512; FLJ21439; KIAA1840; Spastic paraplegia 11 (autosomal recessive); Spastic paraplegia 11; Spastic paraplegia 11 protein; Spatacsin; SPG 11; Spg11; SPTCS\_HUMAN.

研究领域： 肿瘤 细胞生物 表观遗传学

抗体来源： Rabbit

克隆类型： Polyclonal

交叉反应： Human, Mouse, Dog, Pig, Cow,

产品应用： ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

分子量： 279kDa

细胞定位： 细胞核 细胞浆 细胞膜

性状： Lyophilized or Liquid

浓度： 1mg/ml

免疫原： KLH conjugated synthetic peptide derived from human SPG11:2151-2250/2443

亚 型 : IgG

纯化方法 : affinity purified by Protein A

储 存 液 : 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

保存条件 : Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

PubMed : PubMed

产品介绍 : The protein encoded by this gene is a potential transmembrane protein that is phosphorylated upon DNA damage. Defects in this gene are a cause of spastic paraplegia type 11 (SPG11). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]

**Subunit:**

Interacts with AP5Z1, AP5B1, AP5S1 and ZFYVE26.

**Subcellular Location:**

Membrane. Cytoplasm > cytosol. Nucleus. Mainly cytoplasmic.

**Tissue Specificity:**

Expressed in all structures of brain, with a high expression in cerebellum.

**Post-translational modifications:**

Phosphorylated upon DNA damage, probably by ATM or ATR.

**DISEASE:**

Defects in SPG11 are the cause of spastic paraplegia autosomal recessive type 11 (SPG11) [MIM:604360]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

**SWISS:**

Q96JI7

**Gene ID:**

80208

**Important Note:**

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

**产品图片**

